Fiera Capital Corp lessened its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 9.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,080,137 shares of the company's stock after selling 814,295 shares during the quarter. Fiera Capital Corp owned about 0.42% of Kenvue worth $173,965,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Park Avenue Securities LLC purchased a new stake in Kenvue in the 3rd quarter valued at about $308,000. Assetmark Inc. purchased a new stake in shares of Kenvue in the third quarter valued at approximately $33,000. Allspring Global Investments Holdings LLC bought a new position in Kenvue in the third quarter worth approximately $22,385,000. Perigon Wealth Management LLC purchased a new position in Kenvue during the 3rd quarter worth $217,000. Finally, Yousif Capital Management LLC bought a new stake in Kenvue during the 3rd quarter valued at $5,425,000. Institutional investors own 97.64% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on KVUE shares. HSBC upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a "hold" rating in a research report on Wednesday, May 8th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a "neutral" rating and a $20.00 price target for the company. JPMorgan Chase & Co. lowered their price target on shares of Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 9th. William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a "market perform" rating for the company. Finally, Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $24.38.
Read Our Latest Report on KVUE
Kenvue Price Performance
Shares of Kenvue stock traded down $0.13 on Friday, reaching $20.47. The company's stock had a trading volume of 30,831,686 shares, compared to its average volume of 18,712,643. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.43. The company has a market capitalization of $39.20 billion and a P/E ratio of 26.24. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $20.03 and a 200-day moving average price of $20.16.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. The business's revenue for the quarter was down 24.9% on a year-over-year basis. Analysts expect that Kenvue Inc. will post 1.18 EPS for the current year.
Kenvue Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Tuesday, May 7th. Kenvue's dividend payout ratio is currently 102.56%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
